Pharma Focus Asia

FUJIFILM Diosynth Biotechnologies Opens New Biopharmaceutical CDMO Facility In North America

Introduction:

FUJIFILM Diosynth Biotechnologies plans for the construction of largest cell culture biophramaceutical CDMO facility. The facility will be located in North America.

Features:

The new, state-of-the-art facility consists of large-scale cell culture manufacturing of bulk drug substance production with 8 x 20,000L bioreactors.

This facility having the potential to expand will add further 24 x 20,000L bioreactors. Moreover, it expands and further add  24 x 20,000L bioreactors.

The new biopharmaceutical facility also consists of automated fill-finish, commercial-scale, packaging and labelling services. In addition, the new facility will have the ability to produce life-impacting medicines.

The new facility is expected to be completed and fully opeartional by spring 2025. Once the construction is completed it is expected to create 725 new jobs.

Specifications:

NameFUJIFILM Diosynth Biotechnologies
TypeNew Construction
Year2025
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024
Want better clinical trial outcomes?